Patent ID: 11951172
Assignee: CRESCENDO BIOLOGICS LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 20:
21. An isolated human heavy chain variable domain (VH) single domain antibody that binds to human LAG-3 comprising a CDR1 sequence as shown in SEQ ID NO: 1, a CDR2 sequence as shown in SEQ ID NO: 2 comprising a N to S substitution in CDR2 at position 57 of the sequence as shown in SEQ ID NO: 4 and a S to T substitution in CDR2 at position 58 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown in SEQ ID NO: 3,_or a CDR1 sequence as shown in SEQ ID NO: 1, a CDR2 sequence as shown in SEQ ID NO: 2 comprising a N to I substitution in CDR2 at position 54 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown in SEQ ID NO: 3, or a CDR1 sequence as shown in SEQ ID NO: 1 comprising a Y to F substitution in CDR1 at position 32 of the sequence as shown in SEQ ID NO: 4, a CDR2 sequence as shown in SEQ ID NO: 2 comprising a S to T substitution in CDR2 at position 58 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown in SEQ ID NO: 3, or a CDR1 sequence as shown in SEQ ID NO: 1 comprising a Y to F substitution in CDR1 at position 32 of the sequence as shown in SEQ ID NO: 4, a CDR2 sequence as shown in SEQ ID NO: 2 comprising a G to S substitution in CDR2 at position 55 of the sequence as shown in SEQ ID NO: 4, a G to D substitution in CDR2 at position 56 of the sequence as shown in SEQ ID NO: 4, a N to I substitution in CDR2 at position 57 of the sequence as shown in SEQ ID NO: 4, a S to T substitution in CDR2 at position 58 of the sequence as shown in SEQ ID NO: 4, and a G to A substitution in CDR2 at position 59 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown in SEQ ID NO: 3, or a CDR1 sequence as shown in SEQ ID NO: 1 comprising a Y to F substitution in CDR1 at position 32 of the sequence as shown in SEQ ID NO: 4, a CDR2 sequence as shown in SEQ ID NO: 2 comprising a S to T substitution in CDR2 at position 58 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown in SEQ ID NO: 3 comprising a S to V substitution in CDR3 at position 106 of the sequence as shown in SEQ ID NO: 4 and a S to A substitution in CDR3 at position 108 of the sequence as shown in SEQ ID NO: 4, or a CDR1 sequence as shown in SEQ ID NO: 1, a CDR2 sequence as shown in SEQ ID NO: 2, and a CDR3 sequence as shown in SEQ ID NO: 3 comprising a A to T substitution in CDR3 at position 107 of the sequence as shown in SEQ ID NO: 4, or a CDR1 sequence as shown in SEQ ID NO: 1, a CDR2 sequence as shown in SEQ ID NO: 2 comprising a G to D substitution in CDR2 at position 56 of the sequence as shown in SEQ ID NO: 4, a N to S substitution in CDR2 at position 57 of the sequence as shown in SEQ ID NO: 4, and a S to T substitution in CDR2 at position 58 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown in SEQ ID NO: 3.